Bioxytran Inc (BIXT)

[Retire43]

From the 10Q:

Found on page 16 .

ProLectin-M’s clinical data shows non-toxicity and efficacy for treatment of mild to moderate COVID-19. The results of the trial are described in our three peer-reviewed articles “Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial”, published in Journal of Vaccines & Vaccination on December 30, 2020, “Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity” published in the International Journal of Health Sciences on July 31, 2022 and “PLG-007 and Its Active Component Galactomannan-a Competitively Inhibit Enzymes That Hydrolyze Glucose Polymers” published in the International Journal of Molecular Science on July 13, 2022. The Company is currently working on a Phase III clinical trial with the CDSCO in India, and is preparing its IND with the FDA.

The clinical trials are expected to take place in August through September, 2022. Further, the Company is also preparing an CDSCO submission for a second drug candidate, ProLectin-I, with similar galectin blocking capabilities as the oral drug, ProLectin-M, but IV-injectable for pulmonary fibrosis. The initial Phase I/II clinical trial for ProLectin-I is planned for August through October, 2022. The described clinical trials are subject to additional funding.

——-
Please note the pulmonary fibrosis is a new drug

The ProLectin is one in oral dose the other is an Intravenous drug